3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1
4
Phase 2/3
2
Phase NA
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
3
Endocrine
3
Thoracic
2
Plasma cell
2
Other hematologic neoplasm
2
Myeloid
2
Gynecologic
2
Gastrointestinal
2
CNS
2
Lymphoid
1
Dermatologic
1
Conditions
Glioblastoma
15
Brain Neoplasms
15
Glioma
9
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Neoplasms by Site
5
Neoplasms by Histologic Type
5
Hematologic Neoplasms
5
Recurrence
4
Neuroblastoma
4
Astrocytoma
4
Spinal Cord Neoplasms
3
Lymphoproliferative Disorders
3
Lung Neoplasms
3
Colorectal Neoplasms
3
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Neurofibromatosis 1
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Melanoma
2
Medulloblastoma
2
Lymphoma
2
Laryngeal Neoplasms
2
Erdheim-Chester Disease
2
Central Nervous System Neoplasms
2
cyclopia sequence
1
Vitamin D Deficiency
1
Interventions
trametinib
1
dabrafenib
1
cobimetinib
1
Vemurafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Thyroid Carcinoma, Anaplastic
×
CNS
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled